Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | GPR6 | P46095 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20524696 | 0.88 | NR4A2 (0.38) | GAAF2GPR6MAPTKMT2A | |
| SCHEMBL22712271 | 0.85 | POLB (0.40) | GAAGPR6KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL20524692 | 0.85 | MAPT (0.39) | GAAF2MAPTKMT2AMEN1 | |
| SCHEMBL29002480 | 0.84 | NNMT (0.35) | GAAGPR6KMT2AMEN1ALDH1A1 | |
| SCHEMBL5653038 | 0.80 | GAA (0.42) | GAAF2MAPTKMT2AMEN1 | |
| SCHEMBL30953772 | 0.77 | AADAT (0.46) | GAAKMT2AMEN1ALDH1A1L3MBTL1 | |
| SCHEMBL24828263 | 0.73 | TSHR (0.43) | GAAMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL20524617 | 0.73 | KMT2A (0.42) | GAAGPR6KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL29002512 | 0.72 | KMT2A (0.36) | GAAGPR6KMT2AKDM4EMAP3K5 | |
| SCHEMBL21723831 | 0.71 | MAP3K5 (0.43) | GAAALDH1A1KDM4ENPSR1MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3600312-B1 | PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2023-05-17 | — | — | EP | disclosed |
| CN-110520127-B | Piperidinyl-substituted and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6 | 武田药品工业株式会社 | 2023-05-16 | — | — | CN | disclosed |
| US-11426397-B2 | Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-08-30 | — | — | US | disclosed |
| US-20200375969-A1 | PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 | TAKEDA CALIFORNIA, INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200375969-A1 | PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 | TAKEDA CALIFORNIA, INC. | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11426397-B2 | Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6 | GPR6, GPR3, GPR68 | GAA 1751/4885F2 4338/4885GPR6 1/4885 |
| US-20200375969-A1 | PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 | GPR6, GPR3, GPR68 | GAA 1751/4885F2 4338/4885GPR6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.